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Summary 
A human myeloid cell subline, P39 +, is found to be a target for human complement (C) via 
the alternative pathway and to allow the deposition of multiple C3 fragments on its membranes, 
though expressing the complement regulatory proteins decay-accelerating factor and membrane 
cofactor protein. The parent cell line, P39-, which is phenotypically similar to the P39 + sub- 
line, does not allow the deposition of homologous C3 fragments. In this study, we established 
a monoclonal antibody, M161 Ab, which reacted with P39 + but not P39- cells. This Ab rec- 
ognized a 43-kD protein in P39 + cell lysate transblotted onto nitrocellulose.  Using this Ab as 
a probe, we purified the 43-kD protein, namely, M161 antigen (Ag). M161 Ag had a basic iso- 
electric point (pI), 9.3-9.4 by chromatofocusing, and was precipitated as an insoluble material 
at the pI point. The purified M161 Ag was a single-chain protein and did not possess N- or 
O-linked carbohydrates.  When the purified M161 Ag was transblotted onto nitrocellulose and 
incubated with Mg2+-EGTA serum, human C3 fragments were efficiently deposited on M161 
Ag. The major species of the deposited C3 fragments was C3b. Furthermore, the C3 fragments 
bound to the M161 Ag were detached by 1 M hydroxylamine, suggesting that a covalent ester 
linkage sustains  M161 Ag-C3b  interaction.  NH2-terminal  amino acid  analysis revealed that 
M161Ag is a novel membrane protein. Hence, it appeared that M161 Ag is a potent activator 
of human alternative  complement pathway on human cells that activates homologous C3 and 
allows the deposition of C3b on itself. Thus, under some conditions, homeostasis of complement 
is maintained even on human cells, not only by the complement regulatory proteins, but also 
by membrane C3-activating molecules on which C3b is deposited. 
T 
he  alternative  complement pathway  has  been  char- 
acterized  as a humoral system of natural immunity to 
invading pathogenic microorganisms and virus-infected cells 
(1). Recognition and subsequent activation of the alternative 
C pathway results in the covalent attachment of C3 fragments 
to  target  membranes, which facilitates  interaction of the 
pathogens with C3 receptor-bearing host effector cells and 
successive C activation into target cell lysis (2). C3 deposi- 
tion is usually observed in foreign material, and the mole- 
cules responsible for the acceptance of human C3b have been 
identified (3-6).  As an exceptional event, human C3 is de- 
posited on human B lymphoid cells bearing CR2 (7-9), the 
mechanism and physiological role of which largely remain 
to be elucidated. 
The mechanism of C3 activation and deposition on bio- 
logical targets has been throughly investigated and addressed 
as the reaction involving the cleavage of the intramolecular 
thioester bond of native C3 accompanied by proteolytic acti- 
vation of C3 to C3b and formation of a covalent linkage of 
C3b with hydroxyl or amino groups on target molecules (2). 
C3 activation is amplified by the deposited C3b via the alter- 
native pathway (2). Regulation of C3 fragment deposition 
is controlled by serum and membrane-bound complement 
regulatory proteins, factor H (10), properdin (11), Ckl (12), 
decay-accelerating factor (DAF) 1 (13), and membrane cofactor 
protein (MCP) (14), as well as membrane constituents such 
as sialic acids (15) and gangliosides  (16). 
We  demonstrated that  a  human  myeloid cell  subline, 
1 Abbreviations  used in this paper:  C3M^, methylamine-treated  C3; DAF, 
decay-accelerating factor; GVB, gelatin veronal buffer; HRP, horseradish 
peroxidase; MCP, membrane cofactor protein; NFIS, normal human serum; 
p-APMSF, (p-amidinophenyl)methanesulfonyl  fluoride hydrochloride. 
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alternative pathway despite the expression of normal DAF 
and MCP (17), and that they expressed C3-activating mem- 
brane molecules distinct from CR2 (18), which is the only 
identified molecule capable of  inducing C3 deposition on some 
Burkitt's lymphoma cell lines  (8).  In addition, P39 + cells 
tend to self-aggregate, whereas parent normal P39 cells (desig- 
nated as P39- cells) grow separately (18). On P39 + cells but 
not P39- cells, C3b remained undegraded for relatively long 
periods when associated with these membrane proteins, and 
significant  amounts of C5a are released when P39 + cells are 
incubated with human serum containing Mg2+-EGTA  (the 
source of the alternative C pathway) (18). P39- cells do not 
activate homologous C  (18).  Thus, in P39 + cells,  the C3b 
bound to the membrane proteins must have the ability to 
assemble in the C3/C5 convertase, thus overcoming the regula- 
tory functions of factor H, DAF, and MCP.  In this study, 
we developed a mAb that reacted with P39 + but not P39- 
cells. Using this mAb as a probe, we. purified a P39 + cell 
membrane protein, which is a homologous C3-activating  mol- 
ecule on human cells. 
Materials  and Methods 
Cells, Antibodies, and Reagents.  Human myeloid cell lines P39-, 
KG-1, and THP1 were provided by the Japanese Cancer Research 
Resources Bank, and HL60 and U937 were gifts from Dr. J. P. 
Atkinson  (Washington  University, St.  Louis, MO).  The P39" 
subline was established as described (18). The cells were usually 
maintained in RPMI-1640 supplemented with 10% FCS (Cell Cul- 
ture Laboratories, Cleveland, OH) in the presence of antibiotics. 
For large scale culture, the P39 + cells were cultured in Hymedium 
910B supplemented with 2% FCS (Nipro Co., Osaka, Japan). Cul- 
tures were kept in an atmosphere of 5% CO2/95% air at 37~ 
Two sublines of P39, P39 + and P39-, were maintained as previ- 
ously described (18). P39- cells grow as a separate form and do 
not induce homologous  C3 deposition  (17, 18). mAbs  against 
human C3b (C-5G), C3bi (G-3E) (19), and MCP (M177) (20) were 
prepared as described. Anti-DAF mAb IA10 (21) was a gift from 
Dr. T. Kinoshita (Osaka University, Osaka, Japan). Rabbit poly- 
clonal  Ab  against P39-  cells was  prepared  in  our laboratory 
(Center for Adult Diseases, Osaka). A rabbit was immunized in- 
traarterially with 107 P39-  cells twice at 7-d intervals, followed 
by three intraveneous injections with P39- cells at 7-d intervals. 
After the last immunization,  blood was drawn from an ear vein 
three times at 3-d intervals. IgG was purified by ammonium sul- 
fate precipitation followed by protein A-Sepharose column chro- 
matography, then coupled to BrCN-activated Sepharose  4B. FITC- 
conjugated goat F(ab)'z of anti-mouse  IgG was purchased from 
Cappel Laboratories (West Chester, PA), and HRP-labeled goat 
anti-mouse IgG was from Bio-Rad Laboratories (Richmond, CA). 
Mouse IgG and goat IgG were from Sigma Chemical Co. (St. louis, 
MO). Recombinant human TNF-cr (sp act 10  s U/m1) was a gift 
from Dainippon  Seiyaku Co., Ltd.  (Osaka, Japan). 
Proteins, Buffers, and Human  Serum.  MCP was purified from 
K562 cells as described (22). DAF was purified from human eryth- 
rocyte membranes by butanol extraction followed  by Q-Sepharose, 
hydroxylapatite, and anti-DAF mAb affinity column chromatog- 
raphy (13, 21). Human C3 was purified by the method of  Nagasawa 
and Stroud  (23), and methylamine-treated C3 (C3MA) was pre- 
pared as described (24). SDS-PAGE  marker proteins were purchased 
from Daiichi Pure Chemical Co., Ltd. (Tokyo, Japan). 
Gelatin veronal-buffered  (GVB) saline containing 2 mM MgC12 
and 10 mM EGTA (Mg2+-EGTA-GVB)  or 10 mM EDTA (EDTA- 
GVB) was used in the assay of C3 deposition (18, 25). Normal 
human serum (NHS) was collected from 40 healthy donors and 
stored in aliquots at  -70~  A  1:20 volume of 40 mM Mg  2+ 
-200 mM EGTA (pH 7.4) or 200 mM EDTA (pH 7.4) was added 
to NHS to prepare Mga+-EGTA-NHS or EDTA-NHS. 
Preparation of a mAb Against a C3-activating Molecule on P39 + 
Cells.  The complexes of C3 fragments and C3 accepting mem- 
brane molecules were partially purified as follows. P39 § cells (5 
x  109) were incubated in 25% Mg2+-EGTA-NH8 for 30 min at 
37~  Cells bearing C3 were washed and solubilized with 1% NP- 
40/DPBS containing 10 mM EDTA, 25 mM iodoacetamide, and 
2 mM PMSF for 30 min at room temperature and centrifuged at 
10,000g for 20 rain. The supernatants were applied to a polyclonal 
anti-P39-  cell Ab-coupled  Sepharose column equilibrated with 
PBS containing  0.05%  NP-40 and 0.2  mM (/,-amidinophenyl) 
methanesulfonyl fluoride  hydrochloride  (p-APMSF). The pass- 
through fraction was then applied to an anti-C3b mAb--coupled 
Sepharose column equilibrated with the same buffer. The column 
was sequentially washed with equilibration and high salt buffers 
(containing  0.6  M  NaC1). The complexes with C3  fragments 
and membrane  proteins were eluted with 0.17 M  glycine-HC1 
buffer, pH 2.5, containing 0.05% NP-40 and 0.2 mM p-APMSF, 
dialyzed against 0.05 M ammonium bicarbonate/0.01% SDS, then 
lyophilized. 
mAb was produced by the method of K6hler and Milstein (26). 
8-wk-old female  BALB/c  mice were subcutaneously  immunized with 
partially purified complexes of C3 fragments and membrane pro- 
teins in CFA three times, followed by two subcutaneous injections 
of the complexes in IFA in a 2-too period. 10 d later, the mice were 
injected intraperitoneally with 107 P39 + cells. For the final booster, 
107 P39 + cells were given intraperitoneally 1 wk after the cell in- 
jection. 3 d later, the spleen was extracted, and the cells were fused 
with mouse myeloma cell line NS-1 (26). 
Hybridoma  clones that secreted antibodies against P39 + cell 
membrane molecules but not P39- cells or human C3 fragments 
were selected by subtractive screening by use of the protein A-ro- 
sette assay (27). The clones producing a mAb that reacted with 
P39 + but  not  P39-  cells were additionally confirmed by flow 
cytometry using the two sublines. The selected  hybrids were cloned 
by limiting  dilution.  The mAb M161(3q, r), was obtained and 
purified from mouse ascites by ammonium sulfate  precipitation fol- 
lowed by DEAE-Sephacel ion exchange chromatography  (28). 
Purification ofM161 Ag.  P39 + cells (5  x  109)  were solubilized 
with 1% NP-40, 25 mM iodoacetamide, 10 mM EDTA, and 2 mM 
PMSF in DPBS for 30 min at room temperature. Cell lysates were 
centrifuged at  10,000 g for 10 min,  then the supernatants were 
diluted to 1:2.5 with ice cold PBS containing 0.5 mM p-APMSF 
and applied to mouse IgG-coupled  Sepharose equilibrated with 
PBS/0.02% NP-40/0.2 mM p-APMSF. The pass-through fraction 
was dialyzed against 20 mM PB/20 mM NaC1/0.02%  NP-40/ 
0.2 mM p-APMSF, pH 7.5, overnight at 4~  then applied to a 
Q-Sepharose column (2.5  x  15 cm) equilibrated with the same 
buffer. The column was washed with the starting buffer and eluted 
with a linear NaC1 gradient (20-500 raM) in 500 ml of starting 
buffer. The M161 Ag was monitored by immunoblotting with the 
M161 Ab, and detected in the pass-through fraction. The pH of 
the unbound fraction was adjusted to 6.0 and dialyzed overnight 
against 20 mM PB/0.02%  NP-40/0.2 mMp-APMSF, pH 6.0. In- 
soluble materials were removed by centrifugation at 10,000 g for 
20 rain, and the supernatant was applied to S-Sepharose (column 
2.5  x  15 cm) equilibrated with the same buffer. After the column 
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a linear salt gradient of the starting buffer and 500 mM NaC1 in 
the same buffer (300  ml each). The eluates containing the M161 
Ag were pooled, adjusted to pH 9.4, and dialyzed against 10 mM 
Tris-HC1/0.05%  NP-40/0.2  mM p-APMSF,  pH  9.4.  A  small 
amount of the precipitate was generated during dialysis, from which 
the insoluble material was separated by centrifugation at 10,000 g 
for 20 min and dissolved in PBS/0.05% NP-40/0.2 mMp-APMSE 
The supernatants were applied to a chromatofocusing column (2  x 
80 cm) equilibrated with 10 mM Tris-HC1/0.05% NP-40/0.1 mM 
p-APMSF,  pH 9.4. The column was washed with 20 mM acetate 
buffer/0.05% NP-40/0.1 mMp-APMSF, pH 6.0, in 10% (vol/vol) 
Polybuffer 96 (Pharmacia, Uppsala, Sweden). The M161 Ag was 
eluted at  a pH ranging from 9.3  to 9.4. 
Degl~osylation  of M161  Ag.  The  M161  Ag in  20  mM Tris- 
maleate buffer, pH 6.0, containing 10 mM D-galactono-3~-lactone, 
1 mM calcium acetate, and 0.1% NP-40 was incubated with 50 mU 
of neuraminidase (Sigma Chemical Co.) for I h at 37~  followed 
by incubation with 3 mU of O-glycanase (Genzyme Corp., Boston, 
MA) for 16 h  at 37~  N-glycanase digestion was performed by 
incubating M161 Ag in PBS/0.05% NP-40 with 24 mU of N-gly- 
canase  (Genzyme Corp.)  for 16 h  at 370C (22). 
SDS-PAGE and Western  Blotting.  SDS-PAGE was performed as 
described (29) under nonreducing and reducing conditions. After 
electrophoresis, the resolved proteins were transferred.to nitrocel- 
lulose (30).  The sheet was then blocked with 10% skim milk for 
1 h  at 370C,  then overnight at 40C,  and sequentially incubated 
with  the  appropriate  mAb,  horseradish  peroxidase  (HRP)-con- 
jugated goat anti-mouse IgG, and substrate for HRP (Konica Co., 
Tokyo, Japan). 
Flow Cytometry.  Cells (106) suspended in 50 #1 of DPBS con- 
taining 0.5% BSA (BSA/DPBS) were mixed with 50 Izl of EDTA- 
plasma and 5 #g of mouse IgG or mAb and incubated for 30 min 
at 4~  After washing with BSA/DPBS, the cells were suspended 
in 90 ~1 of BSA/DPBS and incubated with FITC-cunjugated goat 
F(ab)'z of anti-mouse IgG at 4~  After 30 min,  the cells were 
washed twice with DPBS and fixed with paraformaldehyde. The 
samples were analyzed on a cytofluorograph (EPICS Elite, Coulter 
Corp.,  Hialeah,  FL). 
C3 deposition on P39 cells was examined as described (19). Briefly, 
106 cells were incubated with 25% Mg  2*-EGTA-NHS or EDTA- 
NHS for 30 rain at 37~  After washing,  C3 fragments bound 
to the cells were detected with anti-human C3b mAb and FITC- 
labded second Ab. 
Trypsin Digestion.  P39 + cells (5  ￿  106)  suspended in 2 ml of 
DPBS were incubated with various doses of trypsin (Sigma Chem- 
ical  Co.)  or buffer alone for 2  min at  37~  The reaction  was 
stopped by adding 10 ml of 10% FCS-RPMI. After centrifugation 
at 1,000 g for 6 min, the cells were washed once with 10% FCS- 
1LPMI and then 0.5%  BSA-DPBS.  The levels of C3 deposition, 
M161  Ag, MCP,  and DAF were determined by flow cytometry. 
Functional Analysis ofM16I Ag.  Purified MCP, DAF, and M161 
Ag were resolved by SDS-PAGE (10% gel) under nonreducing con- 
ditions and electroblotted onto nitrocellulose.  The sheet was cut 
Figure  1.  Protein A-rosette assay for screening mAb recognizing P39 § but not P39-  cells. The supernatants of hybridoma clones (see Materials 
and Methods) capable of recognizing P39 + but not P39- cells were first selected by protein A-rosette assay, and the hybridoma cells were subjected 
to limiting dilution. One mAb, named M161 Ab, was established by this method.  The rosetting profile of this mAb with P39* cells is shown (upper 
right). The reactivity of this mAb with P39-  cells (lower  right) and that  of control nonimmune mouse IgG with P39+/-  cells (left) are shown. 
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1 h  at 37"C,  then overnight at 40C.  The strips were incubated 
with 25% EDTA-NHS, Mg2+-EGTA-NHS, or C3rr  (50/~g/ml) 
for 60 min at 370C. After three washes with PBS/0.05%  Tween 
20, the strips were soaked with anti-human C3b mAb, anti-human 
C3bi  mAb,  or  control  mAb,  followed  by  HRP-labeled  goat 
anti-mouse IgG to detect the deposited C3 fragments. The purity 
of MCP, DAF, and M161 Ag and reactivity with each mAb were 
confirmed by SDS-PAGE  followed by silver staining or Western 
blotting. 
When hydroxylamine was used, the M161 Ag electroblotted onto 
nitrocellulose  was incubated in 0.1 M NaHCO3, pH 10, with 1 M 
hydroxylamine (31) for 2 h at 37~  after the incubation with 25% 
Mg2+-EGTA-NHS. Since  the  ester bond  was hydrolyzed in  the 
basic buffer, pH 10 even without hydroxylamine, as described pre- 
viously (32), DPBS (pH 7.4) was used as a control buffer. Binding 
of C3 fragments to the M161Ag was detected with anti-human 
C3b mAb and HRP-labeled second antibody. 
Results 
Establishment  and Properties of mAb M161.  By repetitive 
subtractive screening using the two P39 sublines, we obtained 
one mAb,  M161  (311, K),  which  recognized  the cell surface 
molecule expressed on P39 + but not P39-  cells (Fig.  1). The 
flow cytometric profile of M161  Ab-stained P39 + cells was 
not unimodal, suggesting cell-to-cell variation of the expres- 
sion degree of the M161 Ag (Fig.  2).  The M161 Ag was ex- 
pressed in P39 + but  not  in P39-  cells,  while  other  surface 
markers, including  membrane C  regulatory proteins,  MCP, 
and DAF, were similarly expressed on both cell lines, consis- 
tent with previous results (18).  Intercellular adhesion mole- 
cule  1 was expressed,  though  marginally,  in P39 +  but  not 
in P39-  cells, which was the only known phenotypic differ- 
Table  1.  Reactivity  of mAb M161  with Heraatopoietic 
Cell Lines* 
M161  Ag 
Cell line type  positive  M161  Ag negative 
Myeloid  P39 §  P39-,  HL60,  U937,  THP1, 
KG1,  KY821,  KU812 
Dandi,  P32,  Ramos,  Raft, 
CCRF-SB 
MT1,  TALL1,  CCRF-CEM, 
HSB2,  HLCL1,  Moh4 
B lymphoid 
T  lymphoid 
Erythroblastoid  K562,  HEL 
*  Surface expression  of  the  M161 Ag  on  cell lines was  analyzed 
by flow cytometry  as described in Materials and Methods. 
ence between the two sublines (see reference 18). During the 
culture interval,  the level of the M161  Ag was varied in ac- 
cordance with the C3 activating ability in P39 §  cells, while 
expression  of other  cell  surface molecules,  including  DAF, 
MCP, and LFA-1 did not change (data not shown). As shown 
in Table  1,  all cell lines  except for the P39 +  subline  tested 
to date were M161 Ag negative; although not shown in Table 
1,  some premature bone  marrow cells,  particularly promy- 
elocytes  and  metamyelocytes,  were  M161  Ag  positive. 
Immunoblotting  indicated  that  M161  Ab  recognized  a 
43okD  molecule  in  P39 §  cell  lysates  under  reducing  and 
nonreducing  conditions  (Fig.  3).  The lysates of P39-  cells 
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Figure  2.  Flow cytometry of M161 Ag on the P39 sublines. The M161 
Ab established as described in the legend to Fig. 1 was used to detect the 
corresponding Ag by flow cytometry. The level of M161 Ag along with 
those of DAF and MCP expressed on P39 + and P39-  cells was detected 
with each mAb and FITC-labeled goat anti-mouse  IgG. C3 deposition 
was simultaneously assessed by use of the P39 cells treated with Mg  2§ 
EGTA-NHS, and anti-human  C3b mAb and FITC-labeled second Ab. 
Figure  3.  Analysis of the M161 Ag by SDS-PAGE/immunoblotting. 
P39 §  and P39-  cells were solubilized with  1%  NP-40. Samples were 
resolved  by SDS-PAGE  (10% acrylamide)  under nonreducing (left  and center) 
or reducing (right) conditions and electroblotted onto nitrocellulose. Im- 
munoblotting was performed by use of nonimmune mouse IgG (left) or 
the M161 Ab (center and right) for the first Ab and HRP-labeled goat 
anti-mouse  IgG. The arrow indicates the M161 Ag. 
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pearance of the cell surface M161 Ag paralleled the function of trypsin.  P39 + cells were incubated with 0  (l-]), 0.005 (B), 0.01 (U), and 0.02% 
([]) trypsin for 2 min at 37~  After the reaction was stopped by adding 10% FCS-RPMI,  the cells were washed, and the levels of M161 Ag and 
C3 deposition were assessed by flow cytometry. (B) Effect of trypsin (0.02%)  on MCP and DAF expressed on P39 + cells. P39+ cells were incubated 
with 0.02% trypsin or control buffer [Trypsin (-)] then analyzed by flow cytometry  using anti-MCP and anti-DAF mAbs. Levels of M161 Ag and 
C3 deposition before and after trypsin exposure are also shown. 
and other myeloid cell lines did not contain the 43-kD pro- 
tein (data not shown). 
The relationship between the expression of the M161 Ag 
and C3 activating ability of P39 + cells was further studied. 
P39 + ceUs  were treated with different doses of trypsin, and 
the levels of the M161 Ag and homologous C3 deposition 
were assessed by flow cytometry. The C3-activating  ability 
of P39 + cells diminished in parallel with the dose of trypsin 
and disappearance of the cell surface M161 Ag (Fig. 4 A). 
The levels of MCP and DAF were not affected by trypsin 
(Fig. 4 B). In another experiment, TNF-ol increased the level 
of M161 Ag, and the degree of C3 deposition was again in- 
creased accordingly (Fig. 5). These results suggested that the 
M161 Ag is closely associated with homologous C3 activa- 
tion on P39 + cells. 
Purification of the M161 Ag from P39 + Cells.  Because  of 
the low affinity of the M161 Ab to the antigen in the P39 § 
solubilized preparation,  immunoaf~nity was not a suitable 
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Figure 5.  Upregulation of M161 Ag and C3 
deposition  on P39 + cells by TNF-c~. P39 + 
cells cultured in medium alone (untreated)  or 
in 50 U/ml of TNF-cx were harvested after 
48 h, and then the levels of M161 Ag, DAF, 
and MCP were analyzed by flow cytometry 
using,  respectively, mAbs and FITC-labded 
second antibody. The level of C3 deposition 
was  also assessed by flow  cytometry using 
anti-human C3b mAb after  the cells were 
treated with 25% Mg2+-EGTA-NHS or 25% 
EDTA-NHS. Shaded histograms  are control 
P39 + cells treated  with nonimmune mouse 
IgG and second antibody  or those treated with 
EDTA-NHS, and then with anti-C3b mAb 
(upper right). TNF-c~ induced marked upregu- 
lation of the levels of M161 Ag and C3 deposi- 
tion but only marginal change in the levels of 
MCP and DAF. Three experiments were per- 
formed and a representative one is shown. Figure 6.  Purification  of  the 
M161 Ag. (A) Elution  profile of the 
M161 Ag from  S-Sepharose. The 
pass-through fraction from Q-Sepha- 
rose (C) was applied to S-Sepharose 
and ehted with a linear NaCI gra- 
dient.  The protein concentration 
was determined in each fraction by 
use of the Pierce protein assay kit 
and is  shown  as  ODs62 nm.  The 
M161 Ag was monitored by immu- 
noblotting,  and the result is shown 
in the inset (fraction numbers are 
indicated). (B) Elution  profile of the 
M161 Ag from a chromatofocusing 
gal. The eluate from  S-Sepharose 
was dialyzed against the buffer for 
chromatofocusing, and then applied 
to the column. The M161 Ag moni- 
tored by immunoblotting was ap- 
parent  at pH 9.3-9.4,  and then it 
tailed  to  the following fractions. 
Protein determination (left) and im- 
munoblotting  (lower  right) were per- 
formed with each fraction as in A. 
The eluates were also silver stained 
(upper  right). The arrow indicates  the 
band corresponding  to  the M161 
Ag. (C) Silver staining and immu- 
noblotting  profiles of each purifica- 
tion step. Column fractions in each 
step were resolved by SDS-PAGE 
(10% gel) under nonreducing  con- 
ditions followed by silver staining 
(left). In the right pand, the same 
fractions  were  analyzed by SDS- 
PAGE/immunoblotting  by use of 
the  M161 Ab  and  HRP-labeled 
second antibody. In lane 5, a dou- 
blet of 30-kD hands is present be- 
sides the main 43-k.D band. This is 
a degradation  product,  since this 
30-kD moiety was increased  during 
storage at 4~ 
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matography,  chromatofocusing,  and  isoelectric  point  (pI) 
precipitation  to purify M161 Ag.  The  solubilized prepara- 
tion was first loaded onto mouse IgG-coupled Sepharose and 
then onto a Q-Sepharose column. M161 Ag was monitored 
by silver staining and Western blotting using the M161 Ab. 
M161 Ag did not bind Q-Sepharose under our conditions. 
The pass-through fraction from Q-Sepharose (Fig. 6 C, lane 
3) was applied to an S-Sepharose column.  M161 Ag bound 
S-Sepharose  and  was  eluted  with  NaC1  at  concentrations 
ranging  from 120 to 300 mM (Fig.  6 A).  A portion of the 
M161  Ag-positive fractions  (Fig.  6  C,  lane 4)  were chro- 
matofocused to determine the pI of the Ag. M161 Ag was 
eluted with Poly buffer 96 at pH 9.3 to 9.4, although tailing 
was evident. As shown in Fig. 6 B, the eluates from the chro- 
matofocusing column still contained a considerable amount 
of low molecular weight  proteins  (see also Fig.  6  C,  lane 
5). Since the pI of the M161 Ag was determined at this step, 
we tried to recover the protein by pI precipitation. The pooled 
S-Sepharose fractions were dialyzed against pH 9.4 buffer over- 
night at 4~  The precipitate generated during dialysis  was 
separated by centrifugation,  and SDS-PAGE showed that  it 
largely consisted of M161 Ag (Fig.  6 C,  lane 6).  We used 
this material to further study M161 Ag. The two bands around 
30-kD in lane 5 (right)  appeared to be degradation products 
of M161 Ag, since they were increased during 4~  storage 
of the crude material. 
Deglycosylation revealed that the M161 Ag did not possess 
N-  or O-linked  carbohydrates  (data  not  shown). 
Functional  Analysis  of M161  Ag.  Purified M161 Ag was 
resolved by SDS-PAGE under  nonreducing  conditions  and 
electroblotted onto nitrocellulose.  Each strip of nitrocellu- 
lose was incubated with EDTA-NHS or Mg2+-EGTA-NHS, 
then bound C3 fragments were detected with  anti-human 
C3b or anti-human  C3bi mAb and HRP-labeled second an- 
tibody. C3 fragments efficiently bound to the M161 Ag during 
incubation  with  Mg2+-EGTA-NHS  but  not  to  purified 
MCP or DAF, which were control C3b-binding membrane 
proteins similarly blotted and incubated. The anti-C3b mAb 
predominantly bound to the 43-kD portion compared with 
the anti-C3bi mAb, suggesting that  C3b is a major species 
of the bound C3 fragments.  No C3 fragments bound M161 
Ag in  the presence of EDTA-NHS  (Fig.  7).  Thus,  human 
C3b binds selectively to the purified M161 Ag via activation 
of the alternative  pathway in a manner  resistant  to factors 
H  and  I  in  NHS. 
We next examined which type of linkage sustained the M161 
Ag-C3b complex. The repetitive washing of the strip with 
high salt buffer did not reduce the C3b deposition. C3 pos- 
sesses a thioester bond in its ot chain,  which mediates  the 
covalent linkage of C3b with target molecules (2). To clarify 
this issue, complexes of M161 Ag and C3 fragments trapped 
onto nitrocellulose paper were exposed to hydroxylamine. As 
shown in Fig.  8,  the amount  of the C3  fragments bound 
to the M161 Ag was decreased ,,o40% by hydroxylamine. Ad- 
ditionally,  methylamine-treated  C3  (C3b  analogue)  or na- 
tive C3 (data not shown) did not bind the M161 Ag (Fig. 
8 A). These results indicate that the C3 fragments are linked 
to  the M161  Ag at least partly via the  specific  ester bond 
formed secondarily to the activation of the alternative com- 
plement pathway. The epitope recognized by the M161  Ab 
may not be in close proximity to the acceptor site for C3b 
on the M161 Ag, since the M161 Ab neither blocked the depo- 
sition of C3b onto the M161 Ag nor lost the reactivity with 
the M161 Ag after the deposition of C3 fragments (Fig.  8). 
Discussion 
These studies were initiated because unidentified molecules 
on the human P39 subline P39 + activated the human alter- 
native C  pathway,  and allowed the deposition  of homolo- 
gous C3 on its membrane (17,  18). Human cells are usually 
protected from homologous C attack, including the key step, 
C3 deposition, by expressing C  regulatory proteins.  Mem- 
brane DAF and MCP and plasma factors H  and I are repre- 
sentative of factors responsible for self-protection against the 
Figure  7.  The ability of M161 
Ag to activate C3 and allow the 
deposition of C3 fragments. Four 
sets of the purified K562 MCP, 
human erythrocyte  DAF, and M161 
Ag (Fig. 6, lane 6) were  simultane- 
ously  resolved  by SDS-PAGE  (10% 
acrylamide)  under nonteducing  con- 
ditions. One of them was stained 
by use of the Bio-Rad  silver  staining 
kit (left), and three of them were 
electroblotted onto nitrocellulose. 
One of the three transblotted sets 
was incubated with 25% EDTA- 
NHS and one with Mg2+-EGTA  - 
NHS for 60 min at 37~  After 
washing, the nitrocellulose  was in- 
cubated with anti-human C3b mAb and HRP-labeled  second  antibody  to detect the deposited  C3 fragments (right). Although not shown in the figure, 
EDTA-NHS did not allow the deposition of C3 on DAF or MCP. The other set was analyzed  by Western blotting with mAb M177, IA10, and M161 
Ab, respectively  (center). 
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the M161 Ag by hydroxylamine. The M161 Ag elec- 
troblotted  onto nitrocellulose was incubated with 25% 
Mg2+-EGTA-NHS (lanes I-4)  or  (C3va~ lane  5)  for 
60 min at 37~  After washing, one set of nitrocellulose 
strips was incubated in DPBS (lane 3) or 1 M hydroxyl- 
amine (HA), pH 10, (hne 4) for 2 h at 37~  The binding 
of C3 fragments  to M161 Ag was then detected with 
anti-C3b mAb (lanes 3-5). The other set of strips was 
reacted with anti-MCP mAb (lane I ) or M161 Ab (lane 
2). (B) Determination of the diminution  of the C3b de- 
posited on M161 Ag by hydroxylamine  treatment. C3 frag- 
ments were fixed on the M161 Ag blotted onto nitrocel- 
hlose as in A. Densitometric analysis was performed for 
the assessment of the C3 fragments deposited onto the 
M161 Ag. The levels of C3 fragment deposition in con- 
trol samples were assumed to be 100%. The bound C3 
was decreased  by ,~40% by hydro~lamine. Two additional 
experiments  are  shown.  Although not  shown in the 
figure, '~20-30% decrease was observed with the pH 10 
buffer alone. (See next page.) 
classical and alternative  pathways of homologous C; there- 
fore, C3 deposition is strictly prohibited, although human 
cells are exposed to an abundant plasma C  source  (2, 32). 
Thus, the molecules that activate homologous  C on P39 mem- 
brane permit the deposition of C3, thus circumventing the 
regulatory action of DAF and MCP. 
We found that 90-, 60-, and 40-kD proteins of P39 + cells 
serve as C3-accepting molecules (18). Judging from the rela- 
tive molecular mass, the M161 Ag is the reported 40-kD pro- 
tein. Although the possibility is not excluded that the other 
two are involved in homologous alternative pathway activa- 
tion, we consider that the M161 Ag is a C3-activating pro- 
tein.  This idea is supported by several lines of evidence: (a) 
no tested cell lines, including the P39-  sublines, which fail 
to induce C3 deposition, express the M161 Ag (Table 1); (b) 
the M161 Ag transblotted onto nitrocellulose allows the depo- 
sition of the C3 fragment, C3b, on itself via ester linkage 
(Figs. 7 and 8); (c) the disappearance of M161 Ag secondary 
to trypsin digestion is in accordance with a decrease of C3 
deposition in P39 + cells (Fig. 4); (d) the expression level of 
the M161 Ag and the degree of C3 deposition are regulated 
in parallel by TNF-o~ (Fig.  5);  and (e) M161 Ag appeared 
not to be a protease that activates C3 directly, since exposing 
M161 Ag with various protease inhibitors did not suppress 
C3 deposition. 
During the investigation of the M161 Ag, the possibility 
was raised that this molecule  is an "activator" of foreign origin. 
We therefore examined the following. First,  chromosomal 
analysis and a viral contamination check were performed with 
our P39 cell lines in Japanese Cancer Research Resources Bank, 
and we confirmed that the cells were unequivocally of human 
origin and without viral infection. Second, the cells were not 
targeted by homologous Ab, suggesting that this is not Ab- 
dependent activation of the alternative pathway (18). Third, 
homologous C activation and subsequent C3 deposition oc- 
curred on this molecule in the absence of Ca  2+ (Fig. 7), thus 
negating the involvement of the lectin pathway (33, 34). These 
findings, together with the fact that the M161 Ag is present 
in bone marrow cells in premature stages, reinforce the no- 
tion that this "activator" is a human gene product. 
A similar activator-like  functional feature has been found 
in human CR2 in some lymphoblastoid cell lines (7-9). In- 
deed, a covalent complex of C3b-CR,2 has been identified 
in the Burkitt's lymphoma cell line, Raji (8). However,  the 
M161 Ag we discovered is distinct from CR2 or its frag- 
ment, since (a) the molecular mass of the M161 Ag was 43 kD 
while that of CR2 is "~140 kD (35); (b) P39 + cells did not 
express CR2 (18); (c) M161 Ab did not recognize CR2 (data 
not shown); and (d) NH2-terminal analysis revealed that the 
M161 Ag is an unregistered protein (data not shown). Hence, 
the M161 Ag is a novel human membrane protein with alter- 
native C pathway-activating ability. Studies on the structure, 
function, and physiological role of this protein are in progress. 
M161 Ab did not block C3b deposition or C3-activating 
ability of the M161 Ag. Several groups have suggested that 
metastable  C3b bound covalently  to a specific portion of 
membrane-bound  biological molecules such as IgG (36), C4b 
(37, 38), and C3b (39). It is important for the protein com- 
plex to maintain a certain tertiary structure for the expres- 
sion of the C3/C5 convertase activity (37-39).  Of note, these 
C3b-accepting molecules all belong to the Ig superfamily, 
short consensus repeat (SCR), or complement C3b/C4b. Al- 
though at present we only have information about the NH2- 
terminal sequence of the M161 Ag, it might also be a member 
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C3b-accepting site. If so, it is not surprising that the M161 
Ab does not block the deposition of homologous C3b, be- 
cause the epitope of this mAb may not be present at dose 
proximity to  the C3b-accepting portion. 
Granulocytes infiltrate inflammatory areas via binding to 
C3b/C3bi deposited on the damaged endothelial cells (40). 
C receptors CR1 and CR3 on granulocytes reportedly par- 
ticipate in this cell infiltration (40, 41).  The importance of 
C and its receptors for malignant cell invasion has also been 
shown in previous reports (42).  The molecules responsible 
for C3 deposition under these conditions remain unidentified. 
Another report has suggested that C3 deposition physiolog- 
ically occurs in damaged cells for facilitating clearance by C 
receptor-positive leukocytes (43-46).  In fact, P39 + sublines 
were established through culture in conditions under which 
most cells died (18). These findings may confer physiological 
importance upon C3 deposition. It contributes to cell inva- 
sion; otherwise, it facilitates  phagocytosis for the dearance 
of cell debris. We present the notion that M161  Ag is one 
of the proteins related to these functions. 
Regardless, C3 deposition is a likely event in cells of cer- 
tain conditions and is strictly regulated in normal cells.  C 
regulatory proteins are reportedly important for such regula- 
tion to maintain homeostasis of C activation and to be a safe- 
guard against cell surface C  activation (10-14,  47,  48).  In 
contrast, here we surmise that not only C inhibitors but also 
activators have a relevant part in homologous C  activation 
and regulation on human cell sufaces, the balance of which 
solidifies  the maintenance of C  homeostasis. 
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